Glen Allen, VA―Richmond-area laboratory GENETWORx has obtained certification to perform its DNA Drug-Response genetic testing on samples collected from patients in the state of New York. The laboratory will begin performing its pharmacogenetic testing panel that includes assays for the drug metabolizing enzymes CYP2D6, CYP2C19, CYP2C9 and heart disease risk factors Factor II, Factor V Leiden and MTHFR for physicians in New York State this month.
The GENETWORx DNA Drug-Response Panel examines a patient’s genetic metabolizer type for several of the most important Cytochrome P450 (CYP) enzymes that activate many commonly prescribed drugs for cardiology, pain management and psychiatry. This certification completes GENETWORx’s state and federal accreditations and allows the laboratory to market to physicians in New York State, one of the largest markets for pharmacogenetic testing in the United States.
Because New York State quality standards for laboratories are of the highest in the nation, many laboratories do not have certification to process samples from physicians in the state. GENETWORx’s certification demonstrates the laboratory’s high standards for quality.
GENETWORx CEO William Miller explained, “The New York State certification demonstrates GENETWORx’s commitment to providing the highest quality laboratory services, and gives us a competitive edge over laboratories that are not certified in New York State.”
GENETWORx is a fully accredited laboratory based in Glen Allen, Virginia. Its mission is to deliver meaningful personalized medicine results to patients and provide health care professionals the necessary tools to leverage their knowledge and truly individualize treatment plans based on a patient’s DNA. Its scientists utilize the latest technology in DNA sequencing to help physicians choose the right medications, at the right dose, and effectively lower overall healthcare expenditures while delivering the best health outcome for the patient. For more information, visit the GENETWORx website at www.genetworx.com.